Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/27528| Title: | Defective Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses in an Immunocompromised Individual With Prolonged Viral Replication. | Austin Authors: | Gordon, Claire L ;Smibert, Olivia C ;Holmes, Natasha E ;Chua, Kyra Y L ;Rose, Morgan T ;Drewett, George P ;James, Fiona L ;Mouhtouris, Effie ;Nguyen, Thi H O;Zhang, Wuji;Kedzierski, Lukasz;Rowntree, Louise C;Chua, Brendon Y;Caly, Leon;Catton, Mike G;Druce, Julian;Sait, Michelle;Seemann, Torsten;Sherry, Norelle L ;Howden, Benjamin P ;Kedzierska, Katherine;Kwong, Jason C ;Trubiano, Jason | Affiliation: | Medicine (University of Melbourne) Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia Centre for Antibiotic Allergy and Research Infectious Diseases Department of Infectious Diseases, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia National Centre for Infections in Cancer, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne, Victoria, Australia Data Analytics Research and Evaluation Centre, Austin Health and University of Melbourne, Heidelberg, Victoria, Australia Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia |
Issue Date: | Sep-2021 | Date: | 2021-08-02 | Publication information: | Open Forum Infectious Diseases 2021; 8(9): ofab359 | Abstract: | We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific immune responses in a patient with lymphoma and recent programmed death 1 (PD-1) inhibitor therapy with late onset of severe coronavirus disease 2019 disease and prolonged SARS-CoV-2 replication, in comparison to age-matched and immunocompromised controls. High levels of HLA-DR+/CD38+ activation, interleukin 6, and interleukin 18 in the absence of B cells and PD-1 expression was observed. SARS-CoV-2-specific antibody responses were absent and SARS-CoV-2-specific T cells were minimally detected. This case highlights challenges in managing immunocompromised hosts who may fail to mount effective virus-specific immune responses. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/27528 | DOI: | 10.1093/ofid/ofab359 | Journal: | Open Forum Infectious Diseases | PubMed URL: | 34514016 | ISSN: | 2328-8957 | Type: | Journal Article | Subjects: | COVID-19 SARS-CoV-2 cellular immunity humoral immunity immunocompromise lymphoma |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.